Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc.

2018-02-21 accesswire
LOS ANGELES, CA / ACCESSWIRE / February 21, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Synergy Pharmaceuticals Inc. (''Synergy'' or ''the Company'') (NASDAQ: SGYP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. (240-0)

INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc.

2018-02-20 accesswire
LOS ANGELES, CA / ACCESSWIRE / February 20, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Synergy Pharmaceuticals Inc. (''Synergy'' or ''the Company'') (NASDAQ: SGYP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. (240-0)

Tracking John Paulson's Paulson & Company Portfolio - Q4 2017 Update

2018-02-20 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s US stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 02/14/2018. Please visit our Tracking John Paulson’s Paulson & Company Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q3 2017. (1077-8)

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc.

2018-02-17 accesswire
LOS ANGELES, CA / ACCESSWIRE / February 17, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Synergy Pharmaceuticals Inc. (''Synergy'' or ''the Company'') (NASDAQ: SGYP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. (240-1)

Synergy Pharmaceuticals: New CEO Aims For Reset

2018-02-16 seekingalpha
On Feb. 15, Synergy CEO Hamilton presented at Leerink’s healthcare conference; it was his first significant public appearance since taking the reins in Q4 2017. (240-4)

SGYP / Synergy Pharmaceuticals, Inc. 8-K (Current Report)

2018-02-15 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 15, 2018   Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter)   Delaware   001-35268   33-0505269 (State or other jurisdiction   (Commission   IRS Employer of incorporation or organization)   File Number)   Identification No.

SGYP / Synergy Pharmaceuticals, Inc. / STATE STREET CORP - 3G (Passive Investment)

2018-02-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING SYNERGY PHARMACEUTICALS INC. (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 871639308 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER P

SGYP / Synergy Pharmaceuticals, Inc. / STATE STREET CORP - 3G (Passive Investment)

2018-02-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING SYNERGY PHARMACEUTICALS INC. (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 871639308 (CUSIP NUMBER) 12/31/2017 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X) RULE 13D-1 (B) ( ) RULE 13D-1 (C) ( ) RULE 13D-1 (D) *THE REMAINDER OF THIS COVER P

SGYP / Synergy Pharmaceuticals, Inc. 8-K (Current Report)

2018-02-13 sec.gov
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 13, 2018   Synergy Pharmaceuticals Inc. (Exact name of registrant as specified in its charter)   Delaware   001-35268   33-0505269 (State or other jurisdiction   (Commission   IRS Employer of incorporation or organization)   File Number)   Identification No.

SGYP / Synergy Pharmaceuticals, Inc. / ORBIMED ADVISORS LLC - 13G/A (Passive Investment)

2018-02-13 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   SCHEDULE 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 3)*   Synergy Pharmaceuticals Inc. (Name of Issuer)     Common Stock (Title of Class of Securities)     871639308 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b) o Rule 13d-1(c) o Rule 13d-1(d)  

SGYP / Synergy Pharmaceuticals, Inc. / ORBIMED ADVISORS LLC - 13G/A (Passive Investment)

2018-02-13 sec.gov
  UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549   SCHEDULE 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 3)*   Synergy Pharmaceuticals Inc. (Name of Issuer)     Common Stock (Title of Class of Securities)     871639308 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b) o Rule 13d-1(c) o Rule 13d-1(d)  

SGYP / Synergy Pharmaceuticals, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
synergypharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 3 )*       Name of issuer:  Synergy Pharmaceuticals Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  871639308     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule i

SGYP / Synergy Pharmaceuticals, Inc. / VANGUARD GROUP INC - 3G/A (Passive Investment)

2018-02-09 sec.gov
synergypharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Schedule 13G   Under the Securities Exchange Act of 1934 (Amendment No.: 3 )*       Name of issuer:  Synergy Pharmaceuticals Inc     Title of Class of Securities:  Common Stock     CUSIP Number:  871639308     Date of Event Which Requires Filing of this Statement: December 31, 2017   Check the appropriate box to designate the rule pursuant to which this Schedule i

SGYP / Synergy Pharmaceuticals, Inc. / CVI Investments, Inc. - SC 13G/A (Passive Investment)

2018-02-09 sec.gov
  CUSIP No: 871639308             SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549           SCHEDULE 13G   (Rule 13d-102)     INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2.   (Amendment No. 1)*   Synergy Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 871639308 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Fili

SGYP / Synergy Pharmaceuticals, Inc. / CVI Investments, Inc. - SC 13G/A (Passive Investment)

2018-02-09 sec.gov
  CUSIP No: 871639308             SECURITIES AND EXCHANGE COMMISSION     Washington, D.C. 20549           SCHEDULE 13G   (Rule 13d-102)     INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2.   (Amendment No. 1)*   Synergy Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 871639308 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Fili


SGYP: Synergy Pharmaceuticals Stock Analysis and Research Report

Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. The company discovered, are developing and control 100% worldwide rights to its proprietary uroguanylin based GI platform, which includes one commercial product, TRULANCE (plecanatide), and a second product candidate, dolcanatide.

TRULANCE (plecanatide)

Its first and only commercial product, TRULANCE™, is approved and marketed in the United States (U.S.), under the trademark name TRULANCE™, as a once-daily treatment for adults with chronic idiopathic constipation, or CIC. In clinical trials, TRULANCE helped improve stool consistency and provide more regular bowel movements. TRULANCE is the only prescription medication for CIC that c...

Click for full article
CUSIP: 871639308